Recent advances in biochemistry and genomics hold the promise of realizing this dream closer than ever before. There has been an explosion in the number of new firms (and increased interest amongst established market players) investigating the potential of harnessing these advances. These new therapeutic interventions will help all of us successfully overcome existing and emerging new health challenges. Ongoing research and the resulting drugs will impact cancer, neurological diseases, auto-immune diseases, and infectious diseases in our lifetime.

In this quest, every bio-pharmaceutical and medical device company needs to stay on top of this fast evolving domain from a scientific and market perspective. They also need to ensure that their operational processes for manufacturing and delivering these promising new drugs meet regulatory standards efficiently.